• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director May Karen J

    5/18/26 5:37:06 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MAY KAREN J

    (Last)(First)(Middle)
    1750 YANKEE DOODLE ROAD

    (Street)
    EAGAN MINNESOTA 55121

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Solventum Corp [ SOLV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Units(1)05/15/2026A3,300 (2) (2)Common Stock3,300$03,300D
    Explanation of Responses:
    1. Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
    2. The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.
    Remarks:
    /s/Megan Bombick, attorney-in-fact for Karen May05/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $SOLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    5/15/2026$94.00Outperform
    Wedbush
    5/14/2026$50.00Buy → Neutral
    UBS
    3/24/2026$60.00Sell
    Rothschild & Co Redburn
    1/26/2026$97.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/20/2026$100.00Neutral → Outperform
    Mizuho
    12/2/2025$100.00Neutral → Buy
    BTIG Research
    10/1/2025$77.00Neutral
    UBS
    9/11/2025$80.00Hold
    Jefferies
    More analyst ratings

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Solventum to Participate in the 2026 Jefferies Healthcare Conference

    EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m. EDT in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pion

    5/27/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Participate in the 2026 BofA Securities Health Care Conference

    ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May 13, 2026, beginning at approximately 10:00 a.m. PDT in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challeng

    5/7/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports First Quarter 2026 Financial Results

    Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

    5/5/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Solventum with a new price target

    Wedbush initiated coverage of Solventum with a rating of Outperform and set a new price target of $94.00

    5/15/26 8:30:16 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum downgraded by UBS with a new price target

    UBS downgraded Solventum from Buy to Neutral and set a new price target of $50.00

    5/14/26 8:07:23 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on Solventum with a new price target

    Rothschild & Co Redburn initiated coverage of Solventum with a rating of Sell and set a new price target of $60.00

    3/24/26 8:51:05 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wendell Amy Mcbride bought $100,344 worth of shares (1,475 units at $68.03), increasing direct ownership by 41% to 5,039 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    3/11/26 6:31:11 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Alban Carlos

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:39:57 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Cox Carrie Smith

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:39:18 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Devore Susan D.

    4 - Solventum Corp (0001964738) (Issuer)

    5/18/26 5:38:52 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    SEC Filings

    View All

    SEC Form SD filed by Solventum Corporation

    SD - Solventum Corp (0001964738) (Filer)

    5/29/26 4:14:39 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Solventum Corp (0001964738) (Filer)

    5/27/26 4:23:24 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Solventum Corp (0001964738) (Filer)

    5/20/26 4:14:28 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Solventum Appoints Heather Knight as Chief Commercial Officer

    ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale

    10/21/25 5:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

    BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

    2/11/25 8:00:00 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Financials

    Live finance-specific insights

    View All

    Solventum Reports First Quarter 2026 Financial Results

    Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

    5/5/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026

    ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Tuesday, May 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:63

    4/14/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

    Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

    2/26/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care